` TENX (Tenax Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

TENX
vs
S&P 500

Over the past 12 months, TENX has significantly outperformed S&P 500, delivering a return of 64% compared to the S&P 500's 12% growth.

Stocks Performance
TENX vs S&P 500

Loading

Performance Gap
TENX vs S&P 500

Loading
TENX
S&P 500
Difference

Performance By Year
TENX vs S&P 500

Loading
TENX
S&P 500
Add Stock

Competitors Performance
Tenax Therapeutics Inc vs Peers

S&P 500
TENX
ABBV
AMGN
GILD
VRTX
Add Stock

Tenax Therapeutics Inc
Glance View

Market Cap
25m USD
Industry
Biotechnology

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company is headquartered in Morrisville, North Carolina and currently employs 8 full-time employees. The firm's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The firm's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for the treatment of pulmonary arterial hypertension (PAH), which is a fatal orphan disease. The firm has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

TENX Intrinsic Value
Not Available
Back to Top